TABLE 2 Summary of the Analysis of Synchronous Colorectal Tumors for P53 Mutation

Patient No.	Tumor No.	p53 Mutation					LOH	IHC
		Exon	Codon	Base Change	Amino Acids
3	T1	5	182	TGC-TAC	Cys-Tyr	transition		rrt;col0
	T2	6	220	TAT-TGT	Tyr-Cys	transition		2+
6	T1	5-8	None					1+
	T2	5	178	CAC-TAC	His-Tyr	transition		2+
7	T1	5	175	CGC-CAC	Arg-His	transition		2+
	T2	5-8	None					0
9	T1	7	244	GGC-AGC	Gly-Ser	transition	+	3+
	T2	5	175	CGC-CGT	Arg-Arg	silent		3+
13	T1	7	240	AGT-GGT	Ser-Gly	transition		0
	T2	7	248	CGG-CAG	Arg-Gln	transition		3+
14	T1	5	145	CTG-CAG	Leu-Gln	transversion	+	2+
	T2		intron6	g-a				1+
15	T1	7	245	GGC-AGC	Gly-Ser	transition	+	3+
		7	248	CGG-CAG	Arg-Gln	transition
		7	253	ACC-ATC	Thr-Ile	transition
	T2	7	246	ATG-GTG	Met-Val	transition		3+
16	T1	5-8	None					0
	T2	7	241	Deletion of C	Stop at codon 246			0
17	T1	7	245	GGC-TGC	Gly-Cys	transversion		3+
	T2	7	241	TCC-TTC	Ser-Phe	transition		3+
19	T1	7	245	GGC-TGC	Gly-Cys	transversion	+	3+
	T2	6	220	TAT-TGT	Tyr-Cys	transition		3+
20	T1	5-8	None					0
	T2	7	244	GGC-AGC	Gly-Ser	transition		3+
21	T1	5-8	None					0
	T2	7	248	CGG-CAG	Arg-Gln	transition		1+
22	T1	7	258	GAA-AAA	Glu-Lys	transition		3+
	T2	5-8	None					3+
23	T1	5	176	TGC-TAC	Cys-Tyr	transition		1+
		7	259	GAC-AAC	Asp-Asn	transition
	T2	6	221	GAG-GGG	Gln-Gly	transition		0
24	T1	6	220	TAT-TGT	Tyr-Cys	transition		1+
	T2	5	175	CGC-CAC	Arg-His	transition	+	0
25	T1		None					0
	T2	6	200	Deletion of T	Stop at codon 246			0

LOH, loss of heterozygosity; IHC, immunohistochemistry; Cys, cystein; Tyr, tyrosine; His, histidine; Arg, arginine; Gly, glycine; Ser, serine; Gln, glutamine; Leu, leucine; Thr, threonine; Ile, isoleucine; Met, methionine; Val, valine; Phe, phenylalanine; Glu, glutamate; Lys, lysine; Asp, asparaginic acid; Asn, Asparagine; +, tumor with LOH; 0, negative tumors; 1+, low expression (1 to 10% immunoreactive tumor cells); 2+, moderate expression (10 to 50% immunoreactive tumor cells); and 3+, high expression (50 to 100% immunoreactive tumor cells).

Search